Galena Biopharma Launches Anti-Nausea Drug Zuplenz

Galena Biopharma shares are up 5% after announcing the launch of an anti-nausea drug known as Zuplenz, indicated for use in post-chemo, post-radiation and post-surgical patients.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.